Preliminary Development and Clinical Evaluation of a Locally Produced ELISA for Urinary Histoplasma Antigen Detection in Argentina
Journal of Pharmaceutical and BioTech Industry · 08.05.2026 · 3 (2) · 10
DOI: 10.3390/jpbi3020010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Pharmaceutical and BioTech Industry, online erschienen am 08.05.2026. Verfasst von Agustín Videla Garrido und 5 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Promoción Científica y Técnica.
Abstract (Originalsprache)
Background
Histoplasmosis is a major opportunistic fungal infection in immunocompromised individuals, particularly people living with HIV in Latin America. Early diagnosis is essential to reduce morbidity and mortality, but commercial urinary Histoplasma antigen assays are not consistently accessible in many endemic settings.
Methods
We developed a locally produced enzyme-linked immunosorbent assay (ELISA) to detect urinary Histoplasma antigen in urine and performed a preliminary clinical evaluation. The assay is based on a sandwich ELISA format using rabbit polyclonal antibodies raised against whole-killed yeast cells of Histoplasma capsulatum. Receiver operating characteristic (ROC) analysis was performed with urine samples from patients with progressive disseminated histoplasmosis (PDH) (n = 37) and healthy controls (n = 20). An exploratory disease-control panel (n = 11) was also tested to assess cross-reactivity. Preliminary analytical characterization included blank-based estimation of the limit of detection (LOD) and limit of quantification (LOQ).
Results
Using a Youden-derived cutoff of OD492 = 0.243, the in-house ELISA showed a sensitivity of 73.0% (27/37; 95% CI: 55.9–86.2%) and a specificity of 100.0% (20/20; 95% CI: 83.2–100.0%) in the main ROC dataset, with an area under the curve of 0.856. In the exploratory disease-control panel, 2 of 11 specimens were reactive (one paracoccidioidomycosis and one cryptococcosis sample). Preliminary LOD and LOQ estimates were 4.46 ng/mL and 8.15 ng/mL, respectively.
Conclusions
This locally developed ELISA represents a feasible and cost-effective alternative for urinary antigen detection of Histoplasma, with potential to improve access to early diagnosis in resource-limited settings. However, its current performance should be considered preliminary. Additional optimization and broader validation, including direct comparison with commercial assays, inter-assay precision, reagent stability, and larger multicenter control panels, are required before routine clinical implementation.
Förderung
- Agencia Nacional de Promoción Científica y Técnica
Zitieren
APA
Garrido, A. V., Briceño, V. F., Laboccetta, C. R., Posse, G. B., Nusblat, A. D., & Cuestas, M. L. (2026). Preliminary Development and Clinical Evaluation of a Locally Produced ELISA for Urinary Histoplasma Antigen Detection in Argentina. Journal of Pharmaceutical and BioTech Industry, 3(2), 10. https://doi.org/10.3390/jpbi3020010
Vancouver
Garrido AV, Briceño VF, Laboccetta CR, Posse GB, Nusblat AD, Cuestas ML. Preliminary Development and Clinical Evaluation of a Locally Produced ELISA for Urinary Histoplasma Antigen Detection in Argentina. Journal of Pharmaceutical and BioTech Industry. 2026;3(2):10. doi:10.3390/jpbi3020010
BibTeX
@article{Garrido2026,
author = {Garrido, Agustín Videla and Briceño, Víctor Fernández and Laboccetta, Carolina Rodríguez and Posse, Gladys B. and Nusblat, Alejandro D. and Cuestas, María L.},
title = {Preliminary Development and Clinical Evaluation of a Locally Produced ELISA for Urinary Histoplasma Antigen Detection in Argentina},
journal = {Journal of Pharmaceutical and BioTech Industry},
year = {2026},
volume = {3},
number = {2},
pages = {10},
doi = {10.3390/jpbi3020010}
}
EUVIMED